May 15, 2026

FY26 Peer Reviewed Medical Research Program funding opportunities are now available!

For the sixth consecutive year, peripheral neuropathy (PN) has been renewed as an eligible condition for research funding by the Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP)’s $127 million fund for FY26. Below are the FY26 funding mechanisms, pre-application and application deadlines, award amounts, maximum direct costs and how to apply.

FY26 Peer Reviewed Medical Research Program award mechanisms and pre-application deadlines:

Clinical Trial Award
- Pre-application deadline: July 23, 2026
- Application deadline: September 22,2026

Discovery Award
- Pre-application deadline: July 16, 2026
- Application deadline: July 30, 2026

Impact Award
- Pre-application deadline: July 23, 2026
- Application deadline: August 6, 2023

Lifestyle and Applied Health Research Award
- Pre-application deadline: July 23, 2026
- Application deadline: August 6, 2023

Platform Clinical Translation Award
- Pre-application deadline: July 23, 2026
- Application deadline: August 6, 2023

Research Advancement Award
- Pre-application deadline: July 16, 2026
- Application deadline: July 30, 2026

Technology/Therapeutic Development Award
- Pre-application deadline: July 23, 2026
- Application deadline: August 6, 2023

Get more information about the FY26 PRMRP, including submission instructions, and APPLY NOW!

Background information

Since our formation in 2007, we have worked to advance peripheral neuropathy research to improve diagnosis, treatment, and management of this debilitating condition. In the first year for PN eligibility, more than $8 million in funding was awarded. Since then, over $25 billion in funding has been awarded for PN research.

The Foundation for Peripheral Neuropathy is a non-profit organization committed to improving the lives of patients living with peripheral neuropathy. We help accelerate the ability to diagnose, treat, prevent, and cure peripheral neuropathies through research funding and increased awareness of this condition. For questions, please reach out to us at [email protected].